CD8A and neoplasm: Antitumoral activity was shown for CXCR4 antagonist BL-8040 in tumor bearing mice, where it induced robust mobilization of CD4+ and CD8+ T lymphocytes and DC in numbers that were significantly higher compared to tumor free naïve counterparts.